PROGRAM. asian interchange on diabetes July in Bangkok, Thailand. Venue Centara Grand at Central World

Size: px

Start display at page:

Download "PROGRAM. asian interchange on diabetes July in Bangkok, Thailand. Venue Centara Grand at Central World"

Mervin Blankenship
5 years ago
Views:

1 PROGRAM asian interchange on diabetes July in Bangkok, Thailand Venue Centara Grand at Central World

2 BANGKOK 2016 JULY 30 & 31 ACROSS T2D Your gateway to the international expert forum for Type 2 Diabetes ACROSS T2D is a global academy for cardiovascular risk, outcomes and safety studies in Type 2 Diabetes (T2D). It has been established as a collaboration with leading international experts to provide education and share best clinical practice among professionals who manage patients with Type 2 Diabetes (T2D). For more information visit us at: Physicians Academy for Cardiovascular Education (PACE-CME) foundation The rationale for establishing the PACE foundation, the Physicians Academy for Cardiovascular Education foundation comes from the recognition that physician education plays an increasingly important role in our efforts to reduce the burden of cardiovascular disease and diabetes. The goal of PACE is to help physicians assimilate the proven findings of scientific research into the day-today practice of clinical medicine, all in the interest of improving outcomes in patients. The mission of PACE-CME is to improve the cardiovascular health of patients by providing an international forum for the review, exchange and assimilation of new important data underlying cardiovascular disease and diabetes and accelerate the translation of this information into clinical practice. For more information visit us at: 2 ASIAN INTERCHANGE ON DIABETES

3 Bangkok, July 2016 On behalf of Boehringer Ingelheim (S) Pte Ltd, ACROSS T2D and the PACE foundation, we welcome you to the 3rd Asian Interchange on Diabetes: Innovation in T2DM: How will novel interventions impact clinical care? Diabetes Clinical Innovation Diabetes and Cardiovascular disease (CVD) have continued to rise to epidemic proportions throughout the world, despite improvements in our understanding and management of these diseases. Patients with diabetes have a high lifetime CVD risk, thus management of these patients should not only focus on control of glycaemia but also address CV risk factors. The conventional approach to managing CVD is aimed at treating the major CV risk factors: diabetes, hypertension, dyslipidaemia, obesity and smoking as separate entities, without understanding how a combination of these can multiply the CV risk. Furthermore, a considerable treatment gap between evidence and practice exists because guidelines recommendations are not adequately implemented. Newer classes of glucose lowering drugs have been developed in recent years. Several ongoing and recently published trials provide guidance that the incretin axis directly or indirectly can lower CVD risk in diabetes. Recently trials with DPP4 inhibitors suggested that oral gliptin therapy is safe in CVD but did not lower CVD risk in the short term. Results of longer term studies with other DPP4 inhibitors and GLP-1 analogue therapies are awaited. Novel data from the new class of SGLT2 inhibitors showed in the EMPA-REG OUTCOME trial positive outcomes on the primary endpoint, which included a reduction in CV mortality. During this Asian Interchange on Diabetes you will receive a balanced review on how all these novel developments might impact your clinical practice in managing your patients with T2DM. Asian Interchange on Diabetes PACE-CME & ACROSS T2D This Asian Interchange on Diabetes is in collaboration with PACE-CME (Physicians Academy for Cardiovascular Education) and ACROSS T2D (Academy for Cardiovascular Risk, Outcomes and Safety Studies in Type 2 Diabetes). The mission of PACE-CME is to improve the cardiovascular health of patients by providing an international forum for the review, exchange and assimilation of new important data underlying cardiovascular disease and diabetes and accelerate the translation of this information into clinical practice. We wish you an interesting and stimulating meeting. PACE-CME Foundation JULY, BANGKOK, THAILAND 3

4 Program itinerary Friday July 29, 2016 Arrivals All day Saturday July 30, 2016 Scientific session 08:30 10:30 hrs Ballroom A&B Coffee break 10:30 11:00 hrs Foyer Scientific session 11:00 12:30 hrs Ballroom A&B Lunch 12:30 13:30 hrs Delegates Café Workshops 13:30 15:00 hrs Ballroom A&B, Lotus Suite 11, Lotus Suite 12 Sunday July 31, 2016 Scientific session 09:00 11:00 hrs Ballroom A&B Coffee break 11:00 11:30 hrs Foyer Optional lunch 11:30 13:00 hrs Delegates Café Departures Lobby 4 ASIAN INTERCHANGE ON DIABETES

5 Address Centara Grand & Bangkok Convention Centre at CentralWorld 999/99 Rama 1 Road, Pathumwan Bangkok 10330, Thailand Check in time: 14:00 hrs Check out time: 12:00 hrs Breakfast: 06:00 10:30 hrs, The World Restaurant, level JULY, BANGKOK, THAILAND 5

6 Educational Agenda Saturday, July 30, 2016 Co-chairmen: Sompongse Suwanwalaikorn, MD Chulalongkorn University, Bangkok, Thailand David Fitchett, MD University of Toronto, Canada 08:30 08:40 Introduction and educational objectives 08:40 09:05 Diabetes in Asia: What is different from the west? Chaicharn Deerochanawong, MD Rajavithi Hospital College of Medicine, Bangkok, Thailand 09:05 09:40 Management of hyperglycemia in type 2 diabetes: Update on novel trends and developments Richard E. Pratley, MD Florida Hospital Diabetes Institute, Orlando, Fl, USA 09:40 10:15 Need for ongoing clinical innovation in management of T2DM: A closer look at the development process of new entities Michael Mark, MD, Boehringer Ingelheim Cardiometabolic Diseases Research 10:15 10:30 Panel discussion All faculty 10:30 11:00 Coffee break Co-chairmen: Sompongse Suwanwalaikorn, MD Chulalongkorn University, Bangkok, Thailand Richard E. Pratley, MD Florida Hospital Diabetes Institute, Orlando, Fl, USA 11:00 11:35 Diabetes and Cardiovascular Disease: A review of new outcome data impacting practice David Fitchett, MD University of Toronto, Canada 11:35 12:10 Understanding Diabetes Kidney Disease: What are the best options for clinical management? Per-Henrik Groop, MD University of Helsinki, Helsinki, Finland 6 ASIAN INTERCHANGE ON DIABETES

7 12:10 12:30 Open forum All faculty 12:30 13:30 Lunch break WORKSHOPS - CASE DISCUSSIONS 13:30 15:00 The clinical challenge of innovations in T2DM management International experts will discuss based on practical case studies the implications of novel developments for patient care Sunday, July 31 MEET THE EXPERTS 09:00 09:30 Update on DPP4 inhibition in T2DM: Implications from recent and ongoing trials Richard E. Pratley, MD 09:30 09:55 CV Protection in the EMPA-REG OUTCOME Trial: A Thrifty Substrate Hypothesis Michael Mark, MD 09:55 10:25 Update on SGLT2 inhibition in T2DM: A closer look at EMPA-REG OUTCOME David Fitchett, MD 10:25 11:00 DEBATE Individualizing the Management of T2DM: who and how? Based on provocative statements reflecting current and future management of T2DM in Asia the panel will have an interactive debate 11:00 Coffee break & end of program JULY, BANGKOK, THAILAND 7

David Fitchett Lectures: Diabetes and Cardiovascular Disease: A review of new outcome data impacting practice Update on SGLT2 inhibition in T2DM: A closer look at EMPA-REG OUTCOME University of

8 David Fitchett Lectures: Diabetes and Cardiovascular Disease: A review of new outcome data impacting practice Update on SGLT2 inhibition in T2DM: A closer look at EMPA-REG OUTCOME University of Toronto, Toronto, Canada Dr. David Fitchett MA MB BChir MD(Cantab) MRCP(UK) FRCP(C) FACC FESC graduated from Cambridge University in the UK in 1970, and continued his clinical training at The Middlesex Hospital Medical School, London. His cardiology training was at The Brompton and Hammersmith Hospitals where he completed his MD thesis in Clinical and Experimental Studies of Heart Muscle Disorders. In 1978 he went to The Royal Victoria Hospital, Montreal where he was director of the CCU and medical director of the cardiac transplant program. He is a fellow of the American College of Cardiology, The European Society of Cardiology and of the Royal College of Physicians of Canada. In 1997 he came to St Michael s Hospital in Toronto as Director of the Cardiac ICU. He remained in that role until Dr Fitchett has over 230 reviewed publications, abstracts, and book chapters. He is a reviewer for many journals including the New England Journal of Medicine, Circulation, American Heart Journal, Nature Medicine, and the Canadian Journal of Cardiology. His research interests are clinical trials in acute coronary syndromes, and the impact of diabetes and metabolic syndrome on heart disease. He is the chair of the macrovascular section of the Canadian Diabetes Guidelines. He is on the steering and on data and safety committees for a number of international clinical trials. Currently Dr Fitchett is an Associate Professor of Medicine at the University of Toronto and a Staff Cardiologist at St Michael s Hospital. 8 ASIAN INTERCHANGE ON DIABETES

Sompongse Suwanwalaikorn Division of Endocrinology and Metabolism Chulalongkorn University, Bangkok, Thailand Associate Professor Sompongse Suwanwalaikorn is Deputy Medical Service Director in the

9 Sompongse Suwanwalaikorn Division of Endocrinology and Metabolism Chulalongkorn University, Bangkok, Thailand Associate Professor Sompongse Suwanwalaikorn is Deputy Medical Service Director in the Division of Endocrinology and Metabolism, Department of Medicine at Chulalongkorn University, Chulalongkorn Hospital, Bangkok, Thailand. He trained at Mahidol University and Ramathibodi Hospital in Thailand and continued his post-graduate training specialising in Endocrinology and Metabolism in the USA at The Diabetes Institutes, Eastern Virginia Medical School, Virginia and at the University of Massachusetts Medical Center, Massachusetts respectively. Associate Professor Suwanwalaikorn s academic and research interest have been focused in the areas of diabetes and thyroid disease, both of which he has published work in academic journals. In addition to his academic research interests Associate Professor Suwanwalaikorn is an active member of a number of professional medical societies pertinent to his interest in endocrinology and diabetes including The Endocrine Society of Thailand, The ASEAN Federation of Endocrine Society (AFES), The American Diabetes Association (ADA) as well as The Royal College of Physicians of Thailand. Associate Professor Suwanwalaikorn is also a member of the Thai Medical Council JULY, BANGKOK, THAILAND 9

10 Chaicharn Deerochanawong Lecture: Diabetes in Asia: What is different from the west? Rajavithi Hospital College of Medicine Bangkok, Thailand Chaicharn Deerochanawong holds a position as a Professor of Medicine in Diabetes and Endocrinology Unit at Rajavithi Hospital, College of Medicine, Rangsit University, Bangkok, Thailand. Currently, he is Scientific Chairman of the Endocrine Society of Thailand, Secretary and committee member of the Thai Obesity Association, and a committee member of both the Thai Atherosclerosis Association and the Royal College of Physicians of Thailand. Prof. Chaicharn Deerochanawong undertook his clinical and research training in Diabetes and Endocrinology at the University of Newcastle Upon Tyne, United Kingdom. He graduated his Medicine from Chulalongkorn University.In 1992, he received grant fellowship of Diabetes and Endocrinology in UK by British Council and in 1996, he received Distinguished research award from Thai Endocrine Society. His scientific interests lie in both clinical and research particularly in the field of diabetes especially diabetes in pregnancy, obesity and dyslipidaemia. He was the Principle Investigator Thailand site of HAPO study (Hyperglycemia and Adverse Pregnancy Outcomes). During his career, Prof. Chaicharn Deerochanawong has presented and lectured at numerous meetings both local and international and contributed to many publications, including over 80 scientific articles. 10 ASIAN INTERCHANGE ON DIABETES

11 Richard E. Pratley Lectures: Management of hyperglycemia in type 2 diabetes: Update on novel trends and developments Update on DPP4 inhibition in T2DM: Implications from recent and ongoing trials Florida Hospital Diabetes Institute Orlando, FL, USA Dr. Richard Pratley is the Medical Director of the Florida Hospital Diabetes Institute (FHDI). He is also Senior Faculty at the Translational Research Institute for Metabolism and Diabetes, as well as a Professor at the Sanford- Burnham Medical Research Institute at Lake Nona in Orlando, Florida. Dr. Pratley has served as Head of the Diabetes and Metabolism Unit of the National Institutes of Health Clinical Diabetes and Nutrition Section in Phoenix, Arizona. He then took a position as Senior Director in the Cardiovascular and Metabolism Therapeutic Area at Novartis Pharmaceuticals where he worked on the clinical development of new drugs for diabetes. From 2004 to 2011, Dr. Pratley was the Director of University of Vermont s Diabetes and Metabolism Translational Medicine Unit and a Professor at their College of Medicine. There he led many large-scale investigations, including NIH and pharmaceutical company sponsored studies. As a member of the American Diabetes Association, the European Association for the Study of Diabetes and The Obesity Society, Dr. Pratley continues his active involvement in the professional community. The Henry Christian Award for Excellence in Clinical Research from the American Federation for Clinical Research Foundation was awarded in recognition of his work. He regularly presents at national and international meetings, has written over 150 peer-reviewed articles and is a Principal Investigator for both NIH and pharmaceutical company sponsored trials in diabetes. He is on the editorial boards of Diabetes Care and Current Diabetes Reports and acts as an ad hoc reviewer for many journals, including the American Journal of Cardiology and Diabetes. Dr. Pratley is a graduate of Wayne State University School of Medicine in Detroit, Michigan, and trained in internal medicine at the University of Michigan in Ann Arbor. He completed Fellowship training in geriatrics and gerontology at the University of Michigan, Johns Hopkins University, and the National Institutes of Health (NIH) National Institute on Aging in Baltimore, Maryland. His current research interests include the prevention of diabetes, improving the care for persons with diabetes, developing new drugs to treat and prevent diabetes and its complications and understanding the role of the fat cell in increasing the risk for diabetes and heart disease JULY, BANGKOK, THAILAND 11

Michael Mark Lectures: Need for ongoing clinical innovation in management of T2DM - A closer look at the development process of new entities CV Protection in the EMPA-REG OUTCOME Trial: A Thrifty

12 Michael Mark Lectures: Need for ongoing clinical innovation in management of T2DM - A closer look at the development process of new entities CV Protection in the EMPA-REG OUTCOME Trial: A Thrifty Substrate Hypothesis Boehringer Ingelheim Cardiometabolic Diseases Research Dr. Michael Mark, PhD is the Vice President and Global Head of CardioMetabolic Diseases Research at Boehringer Ingelheim, Germany. In this role, he is responsible for the research and development of innovative treatments for cardiovascular and metabolic diseases including type 2 diabetes mellitus, obesity, NASH and diabetic microvascular complications like eye diseases as well as kidney diseases. Educated as pharmacist Dr Mark is holding a Ph.D. degree in Pharmacology from the University of Tuebingen in Germany. Dr Mark has more than 30 years experience in the pharmaceutical industry. Early in his career, Dr Mark contributed to the discovery and development of repaglinide, an approved treatment of type 2 diabetes. He pioneered the discovery of the DPP-4 inhibitor linagliptin (Trajenta) and was instrumental in the initiation of the preclinical work for the SGLT2 inhibitor empagliflozin (Jardiance), both compounds globally launched and marketed. Together with his team he developed a competitive portfolio for cardiometabolic treatment options with various preclinical and several clinical developments projects currently ongoing. Dr Mark has been appointed as Project Coordinator for SUMMIT, an Innovative Medicines Initiative (IMI)-sponsored European consortium of 19 academic centers and 6 major pharmaceutical partners, which aims to identify and characterize novel biomarkers and genetic markers for diabetic complications. Dr Mark authored many peer-reviewed publications and meeting contributions and also various book chapters. In addition he holds numerous patents. 12 ASIAN INTERCHANGE ON DIABETES

Helsinki University Central Hospital and Principal Investigator of the Finnish Diabetic Nephropathy (FinnDiane) Study at the Folkhälsan Research Center in Helsinki, Finland.

13 Per-Henrik Groop Lecture: Understanding Diabetes Kidney Disease: What are the best options for clinical management? University of Helsinki Helsinki, Finland Per-Henrik Groop, MD, DMSc, FRCPE is currently a Professor of Nephrology (Chair) at the University of Helsinki, Chief Physician at the Division of Nephrology, Helsinki University Central Hospital and Principal Investigator of the Finnish Diabetic Nephropathy (FinnDiane) Study at the Folkhälsan Research Center in Helsinki, Finland. He also acts as a Professor at the Baker Heart & Diabetes Institute in Melbourne, Australia. He graduated from the University of Helsinki in 1982 and he defended his thesis on The relationship between GIP and beta-cell function in man at the same university in After postdoctoral studies at the Guy s Hospital, University of London, under Professor Giancarlo Viberti, he returned to Helsinki to work as a Consultant of Nephrology. His research is focused on the dissection of the pathogenesis of diabetic complications with special emphasis on diabetic nephropathy. In order to provide a unique set of clinical resources with high power to identify genes and genetic variants associated with diabetic complications, he initiated the large, nation-wide FinnDiane Study in To date this landmark study comprises 8400 patients with type 1 diabetes and their family members recruited via a comprehensive network of 92 hospitals and health care centers throughout Finland. The FinnDiane Research Group represents an inter-disciplinary team of 45 scientists, post-graduate students and other personnel JULY, BANGKOK, THAILAND 13

14 Notes 14 ASIAN INTERCHANGE ON DIABETES

Project Managers: Lieke van Heugten: +31 6 27 08 05 86 Iris van Kaam: +31 6 22 74 05 10 MEDCON International The program is managed by MEDCON International bv under the auspices of the PACE

15 Project Managers: Lieke van Heugten: Iris van Kaam: MEDCON International The program is managed by MEDCON International bv under the auspices of the PACE Foundation. For more information please contact MEDCON International at: Tel + 31 (0) or info@medconinternational.com, P.O. box 916, 2003 RX, Haarlem, The Netherlands. PACE Foundation c/o MEDCON International, P.O. Box 916, 2003 RX Haarlem, The Netherlands, JULY, BANGKOK, THAILAND 15

16 Supported by an educational grant from Boehringer Ingelheim

MASTERCLASS. Masterclass: Nephrology. Masterclass Series pm Wednesday, 18 April 2012

MASTERCLASS. Masterclass: Nephrology. Masterclass Series pm Wednesday, 18 April 2012 MASTERCLASS Masterclass Series 2011 2012 Masterclass: Nephrology 5.00pm Wednesday, 18 April 2012 Royal College of Physicians of Ireland, No. 6 Kildare Street, Dublin 2 On behalf of the Education and Professional